✦ LIBER ✦

534 The Hep573 Study - A Randomized Double Blind Placebo Controlled Trial of Silymarin Alone or Combined With Antioxidants in Chronic Hepatitis C

✍ Scribed by Salmond, Ses J.; George, Jacob; Strasser, Simone I.; Byth, Karen; Batey, Robert G.

Book ID: 122529898
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 188 KB
Volume: 138
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(10)63637-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double blind, placebo cont

A randomized, double blind, placebo controlled trial of interferon-alfa and amantadine versus interferon-alfa alone in the treatment of chronic hepatitis C

✍ Obaid Shakil, A.; Balan, Vijayan; Vargas, Hugo; Gartner, Kay; Rakela, Jorge 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 177 KB

831 RANDOMIZED DOUBLE BLIND PLACEBO-CONT

831 RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL OF NITAZOXANIDE IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4

✍ J.F. Rossignol; S.M. Kabil; Y. El-Gohary; E.B. Keeffe 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 68 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled clinical trial of high-dose interferon-alpha induction treatment combined with ribavirin for chronic hepatitis C in hemophilia

✍ K. Meijer; E. B. Haagsma; J. Van Der Meer; for the CHARIBDIS Study Group 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 216 KB

LETTER: A Randomized, Double-Blind, Plac

LETTER: A Randomized, Double-Blind, Placebo-Controlled Trial of Interferon-α and Amantadine Versus Interferon-α Alone in the Treatment of Patients with Chronic Hepatitis C

✍ Jawad Ahmad; Hugo Vargas; Vijayan Balan; Jorge Rakela; A. Obaid Shakil 📂 Article 📅 2002 🏛 Springer US 🌐 English ⚖ 36 KB

Combination therapy with thymosin α1 and

Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial

✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr

Clinical trial: randomized, double-blind

Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4

✍ J. F. ROSSIGNOL; S. M. KABIL; Y. EL-GOHARY; A. ELFERT; E. B. KEEFFE 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB